In its second R&D alliance this week, Eli Lilly has formed a partnership with Genetic Leap, a startup that focuses on applying artificial intelligence to the discovery of RNA-targeted t
Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.
Novartis is putting $20 million upfront into a near-$1 billion deal with US start-up Lindy Biosciences that aims to convert biologic drugs delivered by infusion into therapies that can be s
BioMarin Pharmaceutical has made a couple of appointments aimed at boosting its pipeline, both internally and externally, with C-suite appointments in charge of R&D and business develop
Retail pharmacy giant Walgreens has signed a five-year contract with the US government – worth up to $100 million – for access to its decentralised clinical trials (DCT) network.
Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.